-
1
-
-
84871995815
-
Standards of medical care in diabetes 2013
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes 2013. Diabetes Care 2013;36(Suppl 1):S11-S66.
-
(2013)
Diabetes Care
, vol.36
, Issue.SUPPL. 1
-
-
-
3
-
-
79959487586
-
Temporal trends in the prevalence of diabetic kidney disease in the United States
-
De Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-2539.
-
(2011)
JAMA
, vol.305
, pp. 2532-2539
-
-
De Boer, I.H.1
Rue, T.C.2
Hall, Y.N.3
Heagerty, P.J.4
Weiss, N.S.5
Himmelfarb, J.6
-
4
-
-
0029076841
-
Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial
-
The Diabetes Control and Complications (DCCT) Research Group
-
The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720.
-
(1995)
Kidney Int
, vol.47
, pp. 1703-1720
-
-
-
5
-
-
0142087597
-
Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study
-
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
-
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167.
-
(2003)
JAMA
, vol.290
, pp. 2159-2167
-
-
-
6
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
7
-
-
33645061521
-
Evidence for renoprotection by blockade of the renin-angiotensin- aldosterone system in hypertension and diabetes
-
Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 2006;20: 239-253.
-
(2006)
J Hum Hypertens
, vol.20
, pp. 239-253
-
-
Karalliedde, J.1
Viberti, G.2
-
8
-
-
42749099562
-
Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease
-
Art. No.CD006257
-
Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006;Issue 4, Art. No.CD006257.
-
(2006)
Cochrane Database Syst Rev
, Issue.4
-
-
Strippoli, G.F.1
Bonifati, C.2
Craig, M.3
Navaneethan, S.D.4
Craig, J.C.5
-
9
-
-
84858316646
-
The impact of reninangiotensin-aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy
-
Hirst JA, Taylor KS, Stevens RJ, et al. The impact of reninangiotensin- aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 2012;81:674-683.
-
(2012)
Kidney Int
, vol.81
, pp. 674-683
-
-
Hirst, J.A.1
Taylor, K.S.2
Stevens, R.J.3
-
10
-
-
38049139424
-
Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease
-
Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.
-
(2008)
Ann Intern Med
, vol.148
, pp. 30-48
-
-
Kunz, R.1
Friedrich, C.2
Wolbers, M.3
Mann, J.F.4
-
12
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
De Zeeuw, D.3
-
13
-
-
0035922447
-
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
-
Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
-
(2001)
N Engl J Med
, vol.345
, pp. 851-860
-
-
Lewis, E.J.1
Hunsicker, L.G.2
Clarke, W.R.3
-
14
-
-
84856703024
-
Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: A systematic review and network meta-analysis
-
Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J. Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012;55: 566-578.
-
(2012)
Diabetologia
, vol.55
, pp. 566-578
-
-
Vejakama, P.1
Thakkinstian, A.2
Lertrattananon, D.3
Ingsathit, A.4
Ngarmukos, C.5
Attia, J.6
-
15
-
-
34249101957
-
Chronic kidney disease and cardiovascular risk
-
Yerram P, Karuparthi PR, Hesemann L, Horst J, Whaley-Connell A. Chronic kidney disease and cardiovascular risk. J Am Soc Hypertens 2007;1:178-184.
-
(2007)
J Am Soc Hypertens
, vol.1
, pp. 178-184
-
-
Yerram, P.1
Karuparthi, P.R.2
Hesemann, L.3
Horst, J.4
Whaley-Connell, A.5
-
17
-
-
84879560586
-
Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus
-
Hayden MR, Sowers KM, Pulakat L, et al. Possible mechanisms of local tissue renin-angiotensin system activation in the cardiorenal metabolic syndrome and type 2 diabetes mellitus. Cardiorenal Med 2011;1:193-210.
-
(2011)
Cardiorenal Med
, vol.1
, pp. 193-210
-
-
Hayden, M.R.1
Sowers, K.M.2
Pulakat, L.3
-
18
-
-
4944251740
-
Advances in pathogenetic mechanisms of diabetic nephropathy
-
Nicholas SB. Advances in pathogenetic mechanisms of diabetic nephropathy. Cell Mol Biol (Noisy-le-grand) 2003;49:1319-1325.
-
(2003)
Cell Mol Biol (Noisy-le-grand)
, vol.49
, pp. 1319-1325
-
-
Nicholas, S.B.1
-
20
-
-
34748859681
-
The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease
-
Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-287.
-
(2007)
Pharmacol Rev
, vol.59
, pp. 251-287
-
-
Kobori, H.1
Nangaku, M.2
Navar, L.G.3
Nishiyama, A.4
-
21
-
-
84860296188
-
Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smadmediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy
-
Liu Z, Huang XR, Chen HY, Penninger JM, Lan HY. Loss of angiotensin-converting enzyme 2 enhances TGF-beta/Smadmediated renal fibrosis and NF-kappaB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 2012;92:650-661.
-
(2012)
Lab Invest
, vol.92
, pp. 650-661
-
-
Liu, Z.1
Huang, X.R.2
Chen, H.Y.3
Penninger, J.M.4
Lan, H.Y.5
-
22
-
-
84863153340
-
Angiotensin II induces epithelial- to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway
-
Chen J, Chen JK, Harris RC. Angiotensin II induces epithelial- to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway. Mol Cell Biol 2012;32:981-991.
-
(2012)
Mol Cell Biol
, vol.32
, pp. 981-991
-
-
Chen, J.1
Chen, J.K.2
Harris, R.C.3
-
23
-
-
84859910851
-
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats
-
Sofue T, Kiyomoto H, Kobori H, et al. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. Am J Hypertens 2012;25:604-611.
-
(2012)
Am J Hypertens
, vol.25
, pp. 604-611
-
-
Sofue, T.1
Kiyomoto, H.2
Kobori, H.3
-
24
-
-
0033018804
-
Altered pressurenatriuresis in obese Zucker rats
-
Fujiwara K, Hayashi K, Matsuda H, et al. Altered pressurenatriuresis in obese Zucker rats. Hypertension 1999;33:1470-1475.
-
(1999)
Hypertension
, vol.33
, pp. 1470-1475
-
-
Fujiwara, K.1
Hayashi, K.2
Matsuda, H.3
-
25
-
-
78349232816
-
Population based screening for chronic kidney disease: Cost effectiveness study
-
Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;341:c5869.
-
(2010)
BMJ
, vol.341
-
-
Manns, B.1
Hemmelgarn, B.2
Tonelli, M.3
-
26
-
-
84859784009
-
Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: A systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline
-
Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012;156:570-581.
-
(2012)
Ann Intern Med
, vol.156
, pp. 570-581
-
-
Fink, H.A.1
Ishani, A.2
Taylor, B.C.3
-
27
-
-
84874644599
-
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
-
Kidney Disease: Improving Global Outcomes (KDIGO)
-
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013;3: 1-150.
-
(2013)
Kidney Int
, vol.3
, pp. 1-150
-
-
-
28
-
-
33845760213
-
K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
-
National Kidney Foundation
-
National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(Suppl 2):S1-S180.
-
(2007)
Am J Kidney Dis
, vol.49
, Issue.SUPPL. 2
-
-
-
29
-
-
84867497463
-
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
-
National Kidney Foundation
-
National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012;60:850-886.
-
(2012)
Am J Kidney Dis
, vol.60
, pp. 850-886
-
-
-
30
-
-
84874656078
-
KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease
-
Kidney Disease: Improving Global Outcomes (KDIGO)
-
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012;2:337-414.
-
(2012)
Kidney Int
, vol.2
, pp. 337-414
-
-
-
32
-
-
33747120659
-
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate
-
Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006;145:247-254.
-
(2006)
Ann Intern Med
, vol.145
, pp. 247-254
-
-
Levey, A.S.1
Coresh, J.2
Greene, T.3
-
33
-
-
65649142017
-
A new equation to estimate glomerular filtration rate
-
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
-
(2009)
Ann Intern Med
, vol.150
, pp. 604-612
-
-
Levey, A.S.1
Stevens, L.A.2
Schmid, C.H.3
-
34
-
-
0024370790
-
Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program
-
The Hypertension Detection and Followup Program Cooperative Group
-
Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Followup Program Cooperative Group. Hypertension 1989;13:I80-I93.
-
(1989)
Hypertension
, vol.13
-
-
Shulman, N.B.1
Ford, C.E.2
Hall, W.D.3
-
35
-
-
0026481126
-
Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects
-
Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. JAMA 1992;268(21):3085-3091.
-
(1992)
JAMA
, vol.268
, Issue.21
, pp. 3085-3091
-
-
Walker, W.G.1
Neaton, J.D.2
Cutler, J.A.3
Neuwirth, R.4
Cohen, J.D.5
-
36
-
-
0028953319
-
Early predictors of 15-year end-stage renal disease in hypertensive patients
-
Perry HM Jr, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995;25:587-594.
-
(1995)
Hypertension
, vol.25
, pp. 587-594
-
-
Perry Jr., H.M.1
Miller, J.P.2
Fornoff, J.R.3
-
37
-
-
0141789624
-
Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis
-
Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244-252.
-
(2003)
Ann Intern Med
, vol.139
, pp. 244-252
-
-
Jafar, T.H.1
Stark, P.C.2
Schmid, C.H.3
-
38
-
-
84879596479
-
-
Kidney Disease Improving Global Outcomes (KDIGO), Available from, Accessed July 13
-
Kidney Disease Improving Global Outcomes (KDIGO). KDIGO reaches consensus on CKD staging. Available from http://www.kdigo.org/news-KDIGO-Consensus-on- CKD-Staging.php. Accessed July 13, 2012.
-
(2012)
KDIGO Reaches Consensus on CKD Staging
-
-
-
39
-
-
84862774040
-
-
Kidney Disease Improving Global Outcomes (KDIGO), Available from, Accessed July 13
-
Kidney Disease Improving Global Outcomes (KDIGO). Kidney Disease: Improving Global Outcomes (KDIGO). Available from http://www.kdigo.org/clinical- practice-guidelines/ckd.phpews-KDIGO-Consensus-on-CKD-Staging.php. Accessed July 13, 2012.
-
(2012)
Kidney Disease: Improving Global Outcomes (KDIGO)
-
-
-
40
-
-
84879576255
-
-
Kidney Disease Improving Global Outcomes (KDIGO), Available from, Accessed July 10
-
Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guidelines: published KDIGO clinical practice guidelines. Available from http://www.kdigo.org/clinical-practice-guidelines/index.php. Accessed July 10, 2012.
-
(2012)
Clinical Practice Guidelines: Published KDIGO Clinical Practice Guidelines
-
-
-
41
-
-
77951735232
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus
-
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575-1585.
-
(2010)
N Engl J Med
, vol.362
, pp. 1575-1585
-
-
Cushman, W.C.1
Evans, G.W.2
Byington, R.P.3
-
42
-
-
0035816018
-
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
-
Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719-2728.
-
(2001)
JAMA
, vol.285
, pp. 2719-2728
-
-
Agodoa, L.Y.1
Appel, L.2
Bakris, G.L.3
-
43
-
-
9844219732
-
Effects of blood pressure control on progressive renal disease in blacks and whites
-
Modification of Diet in Renal Disease Study Group
-
Hebert LA, Kusek JW, Greene T, et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997;30:428-435.
-
(1997)
Hypertension
, vol.30
, pp. 428-435
-
-
Hebert, L.A.1
Kusek, J.W.2
Greene, T.3
-
44
-
-
20244371503
-
Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic
-
A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensinconverting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-946.
-
(2005)
Arch Intern Med
, vol.165
, pp. 936-946
-
-
Rahman, M.1
Pressel, S.2
Davis, B.R.3
-
45
-
-
33644855606
-
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate
-
Rahman M, Pressel S, Davis BR, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006;144:172-180.
-
(2006)
Ann Intern Med
, vol.144
, pp. 172-180
-
-
Rahman, M.1
Pressel, S.2
Davis, B.R.3
-
46
-
-
84055172779
-
Safety and efficacy of low blood pressures among patients with diabetes: Subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial)
-
Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol 2012;59:74-83.
-
(2012)
J Am Coll Cardiol
, vol.59
, pp. 74-83
-
-
Redon, J.1
Mancia, G.2
Sleight, P.3
-
47
-
-
77954374543
-
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease
-
Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-68.
-
(2010)
JAMA
, vol.304
, pp. 61-68
-
-
Cooper-DeHoff, R.M.1
Gong, Y.2
Handberg, E.M.3
-
48
-
-
85037107344
-
-
National Institutes of Health, Available from, Accessed July 11
-
National Institutes of Health. Systolic Blood Pressure Intervention Trial (SPRINT). Available from http://clinicaltrials.gov/ct2/show/NCT01206062. Accessed July 11, 2012.
-
(2012)
Systolic Blood Pressure Intervention Trial (SPRINT)
-
-
-
49
-
-
84862751530
-
-
Healthy People 2020, Available from, Accessed July 13
-
Healthy People 2020. Healthy People 2020 Topics and Objectives: Chronic Kidney Disease. Available from http://www.healthypeople.gov/2020/ topicsobjectives2020/objectiveslist.aspx?topicid=6. Accessed July 13, 2012.
-
(2012)
Healthy People 2020 Topics and Objectives: Chronic Kidney Disease
-
-
-
50
-
-
67649635807
-
Renal and retinal effects of enalapril and losartan in type 1 diabetes
-
Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009;361:40-51.
-
(2009)
N Engl J Med
, vol.361
, pp. 40-51
-
-
Mauer, M.1
Zinman, B.2
Gardiner, R.3
-
51
-
-
67649659279
-
Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials
-
Bilous R, Chaturvedi N, Sjolie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-14.
-
(2009)
Ann Intern Med
, vol.151
, pp. 11-14
-
-
Bilous, R.1
Chaturvedi, N.2
Sjolie, A.K.3
-
52
-
-
82455162519
-
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study
-
Imai E, Chan JC, Ito S, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011;54:2978-2986.
-
(2011)
Diabetologia
, vol.54
, pp. 2978-2986
-
-
Imai, E.1
Chan, J.C.2
Ito, S.3
-
53
-
-
79952373965
-
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
-
Haller H, Ito S, Izzo JL Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917.
-
(2011)
N Engl J Med
, vol.364
, pp. 907-917
-
-
Haller, H.1
Ito, S.2
Izzo Jr., J.L.3
-
55
-
-
34247210073
-
Microalbuminuria: What is it? Why is it important? What should be done about it? An update
-
Chugh A, Bakris GL. Microalbuminuria: what is it? Why is it important? What should be done about it? An update J Clin Hypertens (Greenwich) 2007;9:196-200.
-
(2007)
J Clin Hypertens (Greenwich)
, vol.9
, pp. 196-200
-
-
Chugh, A.1
Bakris, G.L.2
-
56
-
-
67650451498
-
Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration
-
Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009;54:205-226.
-
(2009)
Am J Kidney Dis
, vol.54
, pp. 205-226
-
-
Levey, A.S.1
Cattran, D.2
Friedman, A.3
-
57
-
-
0032525867
-
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
-
Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998;128:982-988.
-
(1998)
Ann Intern Med
, vol.128
, pp. 982-988
-
-
Ravid, M.1
Brosh, D.2
Levi, Z.3
Bar-Dayan, Y.4
Ravid, D.5
Rachmani, R.6
-
58
-
-
77955518102
-
Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: A randomised crossover trial
-
Persson F, Rossing P, Reinhard H, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010;53:1576-1580.
-
(2010)
Diabetologia
, vol.53
, pp. 1576-1580
-
-
Persson, F.1
Rossing, P.2
Reinhard, H.3
-
60
-
-
33645069186
-
Prevention of loss of renal function over time in patients with diabetic nephropathy
-
Barnett A. Prevention of loss of renal function over time in patients with diabetic nephropathy. Am J Med 2006;119:S40-S47.
-
(2006)
Am J Med
, vol.119
-
-
Barnett, A.1
-
61
-
-
58249108731
-
Dual blockade of the renin-angiotensin system for cardiorenal protection: An update
-
Arici M, Erdem Y. Dual blockade of the renin-angiotensin system for cardiorenal protection: an update. Am J Kidney Dis 2009;53:332-345.
-
(2009)
Am J Kidney Dis
, vol.53
, pp. 332-345
-
-
Arici, M.1
Erdem, Y.2
-
62
-
-
0037431774
-
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): A randomised controlled trial
-
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.
-
(2003)
Lancet
, vol.361
, pp. 117-124
-
-
Nakao, N.1
Yoshimura, A.2
Morita, H.3
Takada, M.4
Kayano, T.5
Ideura, T.6
-
63
-
-
70349771914
-
Retraction-Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial
-
Anonymous
-
Anonymous. Retraction-Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2009;374:1226.
-
(2009)
Lancet
, vol.374
, pp. 1226
-
-
-
64
-
-
18244406792
-
Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension
-
Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005;45:880-886.
-
(2005)
Hypertension
, vol.45
, pp. 880-886
-
-
Doulton, T.W.1
He, F.J.2
MacGregor, G.A.3
-
65
-
-
34648820103
-
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial
-
Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-885.
-
(2007)
Kidney Int
, vol.72
, pp. 879-885
-
-
Bakris, G.L.1
Ruilope, L.2
Locatelli, F.3
-
66
-
-
49149087718
-
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
-
Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double- blind, controlled trial. Lancet 2008;372:547-553.
-
(2008)
Lancet
, vol.372
, pp. 547-553
-
-
Mann, J.F.1
Schmieder, R.E.2
McQueen, M.3
-
67
-
-
66649094130
-
Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy
-
Krairittichai U, Chaisuvannarat V. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. J Med Assoc Thai 2009;92:611-617.
-
(2009)
J Med Assoc Thai
, vol.92
, pp. 611-617
-
-
Krairittichai, U.1
Chaisuvannarat, V.2
-
68
-
-
44849114597
-
Aliskiren combined with losartan in type 2 diabetes and nephropathy
-
Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
-
(2008)
N Engl J Med
, vol.358
, pp. 2433-2446
-
-
Parving, H.H.1
Persson, F.2
Lewis, J.B.3
Lewis, E.J.4
Hollenberg, N.K.5
-
69
-
-
67249125166
-
The hazards of dual renin-angiotensin blockade in chronic kidney disease
-
Ku E, Park J, Vidhun J, Campese V. The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med 2009;169:1015-1018.
-
(2009)
Arch Intern Med
, vol.169
, pp. 1015-1018
-
-
Ku, E.1
Park, J.2
Vidhun, J.3
Campese, V.4
-
70
-
-
70349337020
-
Proteinuria: Is the ONTARGET renal substudy actually off target?
-
Ruggenenti P, Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? Nat Rev Nephrol 2009;5:436-437.
-
(2009)
Nat Rev Nephrol
, vol.5
, pp. 436-437
-
-
Ruggenenti, P.1
Remuzzi, G.2
-
71
-
-
66849128220
-
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)
-
Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4:361-368.
-
(2009)
Clin J Am Soc Nephrol
, vol.4
, pp. 361-368
-
-
Fried, L.F.1
Duckworth, W.2
Zhang, J.H.3
-
72
-
-
84879586859
-
-
National Institutes of Health, Available from, Accessed July 10
-
National Institutes of Health. VA NEPHRON-D: Diabetes iN Nephropathy Study. Available from http://clinicaltrials.gov/ct2/show/results/NCT00555217. Accessed July 10, 2012.
-
(2012)
VA NEPHRON-D: Diabetes iN Nephropathy Study
-
-
-
73
-
-
78649929199
-
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy
-
Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010;33:2304-2309.
-
(2010)
Diabetes Care
, vol.33
, pp. 2304-2309
-
-
Persson, F.1
Lewis, J.B.2
Lewis, E.J.3
Rossing, P.4
Hollenberg, N.K.5
Parving, H.H.6
-
74
-
-
65249182083
-
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design
-
Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.
-
(2009)
Nephrol Dial Transplant
, vol.24
, pp. 1663-1671
-
-
Parving, H.H.1
Brenner, B.M.2
McMurray, J.J.3
-
77
-
-
34548084570
-
Normotensive ischemic acute renal failure
-
Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med 2007;357:797-805.
-
(2007)
N Engl J Med
, vol.357
, pp. 797-805
-
-
Abuelo, J.G.1
-
78
-
-
80051801008
-
Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients
-
St Peter WL, Farley TM, Carter BL. Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients. Curr Opin Nephrol Hypertens 2011;20:498-503.
-
(2011)
Curr Opin Nephrol Hypertens
, vol.20
, pp. 498-503
-
-
St Peter, W.L.1
Farley, T.M.2
Carter, B.L.3
|